Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

Mathias J Rummel,Dorothea Kofahl-Krause,Christina Balser,Norbert Niederle,Axel Hinke,Harald Ballo,Martina Stauch,Christoph Losem,Ulrich Von Gruenhagen,Georg Maschmeyer,Ulrich Kaiser,Andre G Banat,Eckhart Weidmann,Manfred Welslau,Gerhard Heil,Juergen Barth,Wolfram Brugger,Heinz A Duerk

doi:10.1200/jco.2012.30.15_suppl.3

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

Mathias J Rummel, Dorothea Kofahl-Krause + Show 16 more

https://doi.org/10.1200/jco.2012.30.15_suppl.3

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2012
Citations: 12

Affiliation: Hochschule Hannover, Hannover Medical School, Praxis für Hämatologie und Onkologie, Klinikum Leverkusen, Carl-Thiem-Klinikum Cottbus, St. Bernward Krankenhaus, Krankenhaus Nordwest, Klinikum Lüdenscheid, Schwarzwald-Baar Klinikum, St. Marien Hospital

#Bendamustine Plus Rituximab #CHOP Plus Rituximab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

3 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Full Text